Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

PUMA Trial: Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced non-small cell lung cancer

A Feasibility Study within DKTK

Project Design, indicating the subprojects S1 - S6
© dkfz.de

Image-guided adaptive radiotherapy (IGART) is the latest, technically most advanced treatment option in radiotherapy (RT). IGART monitors the anatomy of the day by daily imaging and adapts the treatment plan accordingly with the patient lying on the treatment couch. i.e. the online adaptation. In our multi-centric project called PUMA Trial we perform a feasibility study of magnetic resonance guided radiotherapy (MRgRT) and cone beam computer tomography guided radiotherapy (CBCTgRT) of advanced non small cell lung cancer (NSCLC).

This collaborative project is carried out together with Heidelberg University Hospital (UKHD), the University Hospital of the Ludwigs-Maximilian University of Munich (LMU) as well as the University Hospital of the Eberhard Karls University of Tübingen (UKT). All participating institutes are part of the German Cancer Consortium (DKTK).

PUMA Trial and PUMA II Trial (S1)

In stage I (PUMA Trial) we aim at demonstrating the clinical feasibility of the MRgRT and CBCTgRT approaches. Ten patients per institution will receive daily MR- (or CBCT with offline MRI-imaging) with online plan adaptation once weekly or in case major anatomical changes are detected. Patients will be followed-up to assess toxicity, tumor control and patient-reported outcomes for 24 months after treatment.

In stage II (PUMA II Trial), a randomized prospective clinical phase I/II trial will be carried out, which aims at a reduction of cardiac, esophageal and pulmonary toxicity ≥ grade III (according to Common Terminology Criteria for Adverse Events, version 5) compared to the standard, conventional, non-adaptive treatment.

Scientific Projects in Medical Physics (S3 - S6)

To focus on the translational character, the clinical trial (S1) is accompanied by four medical physics research projects (S3 - S6). Their final goal is the development and integration of artificial intelligence (AI)-driven tools to support the adaptive RT treatment process and clinical decision making. Data knowledge and clinical experience is efficiently transferred from the scientific projects into the clinics and back. There is an underlying central database to allow for effective data sharing between all participating institutes.

Contact

Leader

Prof. Dr. Oliver Jäkel (DKFZ)

Leaders of the Subprojects

S1: Prof. Dr. Dr. Jürgen Debus, Prof. Dr. Juliane Hörner-Rieber and Dr. Sebastian Regnery (UKHD)

S2: Prof. Dr. Annette Kopp-Schneider (DKFZ)

S3: Prof. Dr. Guillaume Landry and Dr. Christopher Kurz (LMU)

S4: Prof. Dr. Oliver Jäkel and Dr. Martin Niklas (DKFZ)

S5: Prof. Dr. Oliver Jäkel and Dr. Martin Niklas (DKFZ)

S6: Prof. Dr. Daniela Thorwarth (UKT)

Project Coordinators at DKFZ

Dr. Martin Niklas and Dr. Simone Barthold-Beß

Funding

The project is funded by the German Cancer Aid (Deutsche Krebshilfe; funding number 70114708).

more

© Deutsche Krebshilfe

to top
powered by webEdition CMS